Document Type

Conference Proceeding - Restricted Access

Publication Date


Publication Title

Journal of the American College of Cardiology


BACKGROUND General anesthesia (GA) has been the anesthetic for patients who are at intermediate to high risk for perioperative mortality undergoing transfemoral transcatheter aortic valve replacement (TF-TAVR). TF-TAVR has been performed safely using local anesthetic and conscious sedation (CS) as an alternative to GA. We have adopted a novel anesthetic approach for TF-TAVR using a fascia iliaca block (FIB), supplemented by minimal CS (MCS). Whether FIB-MCS is safe and effective compared with GA for patients undergoing TF-TAVR is currently not known. METHODS This is a retrospective, propensity-matched observational study of consecutive TF-TAVR patients from January 2013 to December 2017. Data were collected from electronic medical records linked with the Society of Thoracic Surgeons (STS) database and the TVT (Transcatheter Valve Therapy) Registry. Primary endpoints were intensive care unit (ICU) and in-hospital length of stay (LOS). Secondary endpoints were: 1) 30-day and 1-year mortality; 2) 30-day hospital readmission rate; 3) incidence of failure of FIB-MCS; 4) operating room time (patient in to patient out); 5) in-hospital safety outcomes; and 6) 30-day and 1-year quality of life (Kansas City Cardiomyopathy Questionnaire [KCCQ-12]). RESULTS A total of 304 patients (47% men, mean age 83 years) underwent TF-TAVR using FIB-MCS (n ¼ 219) and GA (n ¼ 85). Propensity matching identified 162 patients (FIBMCS, n ¼ 108; GA, n ¼ 54). For the primary endpoints, patients receiving FIB-MCS had a shorter ICU LOS (47.6 h vs. 69.1 h; p ¼ 0.004) and in-hospital median LOS (3 days vs. 6 days; p < 0.001). For the secondary endpoints: 1) there was similar 30-day (0% vs. 3.7%; p ¼ 0.11) and 1-year (7.4% vs. 5.6%; p ¼ 0.75) mortality; 2) multivariate analysis showed that FIB-MCS patients were less likely to be rehospitalized for all-causes (odds ratio: 0.32; 95% confidence interval: 0.13 to 0.76); 3) 5 patients (2.3%) required conversion of FIB-MCS to GA intraoperatively; 4) patients receiving FIB-MCS had a shorter operating room time (197.6 56.3 min vs. 245.3 42.9 min; p < 0.001); 5) clinical safety outcomes were similar between the cohorts; and 6) 30-day and 1-year mean KCCQ-12 scores were 2% and 3% higher. CONCLUSION TF-TAVR using FIB-MCS is feasible and safe, with a very low risk for conversion to GA, resulting in shorter operating room time, shorter ICU and in-hospital LOS, lower risk for 30-day rehospitalization, and similar 30-day and 1- year all-cause mortality with a trend




13, Suppl B

First Page



Transcatheter Cardiovascular Therapeutics Abstracts Thirty First Annual Symposium Transcatheter Cardiovascular Therapeutics (TCT)–Abstracts. September 2019. San Diego CA. Abstract: TCT-808

Last Page